Consolidated expertise in vaccine immunogenicity evaluation and safety assessment using serological assays make VisMederi a reliable partner in the development of European projects that involve other Research Centers, Universities, SMEs and Big Pharma.
VisMederi is currently involved in three European research projects:
- (IntranasalPandemic Influenza Vaccine)
Since 2012, VisMederi has been involved in the “NASPANVAC” Project, which includes eight international partners (Research Centres, Universities and SMEs) with the aim of developing a new nasal vaccine for pandemic strains of influenza. The project has enabled the collection of important results, some of which have already been published in international journals. (For example, a study of Chitosan and c-di-GMPasmucosaladjuvants for intranasal influenza H5N1 vaccine. Svindland SC, Pedersen GK, Pathirana RD, Bredholt G, Nøstbakken JK, Jul-Larsen Å, Guzmán CA, Montomoli E, Lapini G, Piccirella S, Jabbal-Gill I, Hinchcliffe M, CoxRJ. Influenza OtherRespirViruses. 2013 Nov;7(6):1181-93).
- (Advanced Immunization Technologies)
The objective of ADITEC – which involves scientists from 43 research institutions in 13 different countries – is the development of innovative technologies for immunization to be used for the next generation of human vaccines. ADITEC, the largest project on vaccines financed with 30 million Euros by the EU, involves prestigious European universities and research institutes together with leading U.S. groups in the field of systems and adjuvant biology. Numerous European pharmaceutical and biotechnology companies, engaged in the study of innovative technologies for the development of more effective and safer vaccines also participate in the consortium. www.aditecproject.com
Biovacsafe is an international project which aims at developing cutting-edge instruments to improve the analysis and monitoring of vaccine safety before and after licensing on the market. The project, has a duration of 5 years and is funded by the Innovative Medicines Initiative (IMI), a public-private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA) for a total of over 30 million Euros of public and private investments. www.biovacsafe.eu